retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Obesity Reports Retatrutide Triple Agonist Research Peptide
Description
Gisbert, J
Most patients find that GI side effects diminish within the first few weeks at each new dose level
Create Accountability Share your goals with a partner, coach, or community for motivation and consistency
Because muscles burn more calories, increasing your strength training and focusing on building muscle can help raise your metabolism again and encourage your body to burn more fat
10.1007/s40279-021-01605-8 [DOI] [PubMed] [Google Scholar] 29
